TC
XENE icon

TwinBeech Capital’s Xenon Pharmaceuticals XENE Stock Holding History

TwinBeech Capital’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-6,445
Closed -$216K – 1017
2025
Q1 		$216K Buy
+6,445
New +$245K ﹤0.01% 652
2024
Q3 		– Sell
-88,711
Closed -$3.46M – 932
2024
Q2 		$3.46M Sell
88,711
-9,331
-10% -$373K 0.07% 264
2024
Q1 		$4.22M Buy
+98,042
New +$4.51M 0.09% 239
2023
Q1 		– Sell
-101,717
Closed -$4.01M – 928
2022
Q4 		$4.01M Buy
101,717
+52,967
+109% +$1.93M 0.08% 302
2022
Q3 		$1.76M Buy
48,750
+37,727
+342% +$1.36M 0.05% 359
2022
Q2 		$335K Sell
11,023
-16,445
-60% -$497K 0.02% 447
2022
Q1 		$840K Buy
27,468
+20,590
+299% +$616K 0.04% 338
2021
Q4 		$215K Buy
+6,878
New +$206K 0.01% 513

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

TwinBeech Capital's XENE Position: Q2 2025 in Review

TwinBeech Capital sold out of Xenon Pharmaceuticals (XENE) in Q2 2025, closing a stake of 6,445 shares — an estimated $216K sold.

TwinBeech Capital first reported a position in XENE in Q4 2021 and held it in 8 quarters. The position peaked at $4.22M in Q1 2024. 206 funds tracked by Wall St. Rank hold XENE as of Q2 2025.

  • TwinBeech Capital reported no remaining Xenon Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • TwinBeech Capital sold 6,445 Xenon Pharmaceuticals shares in Q2 2025, an estimated $216K.
  • TwinBeech Capital first reported a position in Xenon Pharmaceuticals in Q4 2021 and held it in 8 quarters.
  • TwinBeech Capital's Xenon Pharmaceuticals position peaked at $4.22M in Q1 2024.
  • 206 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2025.

Based on TwinBeech Capital's 13F filing for Q2 2025, filed 14 Aug 2025.